EMEA-000019-PIP01-07 - paediatric investigation plan

everolimus
PIPHuman

Key facts

Active Substance
everolimus
Therapeutic area
Oncology
Decision number
P/2/2007
PIP number
EMEA-000019-PIP01-07
Pharmaceutical form(s)
Tablet
Condition(s) / indication(s)
Renal cell carcinoma and pancreatic neuroendocrine tumour
Route(s) of administration
Oral use
Contact for public enquiries

Novartis Europharm Limited

E-mail: paediatric.enquiries@novartis.com
Tel. +41 613241111

Decision type
W: decision granting a waiver in all age groups for all conditions or indications
Decision date

Decision

Share this page